Iris metastasis as resistance mechanism to atezolizumab, carboplatin, and etoposide but responds to additional irinotecan and anlotinib in a small cell lung cancer patient

por Huang, Zhe, Zhang, Yongchang
Publicado 2023

Multi-Task Assignment Method of the Cloud Computing Platform Based on Artificial Intelligence

por Zhang, Yongchang, Geng, Panpan
Publicado 2022

Hepatic veno-occlusive disease related to Gynura segetum: A case report

por Sun, Ziyi, Kang, Jianmei, Zhang, Yongchang
Publicado 2018

EGFR exon 21 L858R as an acquired resistance mechanism to nivolumab in a lung cancer patient originally driver gene‐negative

por Xia, Chen, Zeng, Fanxu, Zhang, Yongchang
Publicado 2019

Immune Responses against Disseminated Tumor Cells

por Peng, Ling, Zhang, Yongchang, Wang, Zibing
Publicado 2021

Lung adenocarcinoma presents with diffuse bone metastasis

por Mi, Jinye, Xu, Qinqin, Zhang, Yongchang
Publicado 2021

ALK ‐rearranged lung adenocarcinoma resistant to alectinib with cauliflower gingival metastasis responds to brigatinib

por Song, Lianxi, Zeng, Liang, Zhang, Yongchang
Publicado 2022

Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient

por Hu, Yijuan, Xiao, Lili, Yang, Nong, Zhang, Yongchang
Publicado 2019

Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation−Mediated Erlotinib R...

por Zhou, Yuling, Zeng, Liang, Yang, Nong, Zhang, Yongchang
Publicado 2020

A new glimpse of FadR-DNA crosstalk revealed by deep dissection of the E. coli FadR regulatory protein

por Zhang, Yongchang, Gao, Rongsui, Ye, Huiyan, Wang, Qingjing, Feng, Youjun
Publicado 2014

Rechallenge with erlotinib in osimertinib-resistant lung adenocarcinoma mediated by driver gene loss: a case report

por Liu, Lingli, Lizaso, Analyn, Mao, Xinru, Yang, Nong, Zhang, Yongchang
Publicado 2020

PIM1 inhibitor synergizes the anti-tumor effect of osimertinib via STAT3 dephosphorylation in EGFR-mutant non-small cell lung cancer

por Sun, Ziyi, Zeng, Liang, Zhang, Miaomiao, Zhang, Yongchang, Yang, Nong
Publicado 2020

Novel AMBRA1-ALK fusion identified by next-generation sequencing in advanced gallbladder cancer responds to crizotinib: a case report

por Zhou, Yuling, Lizaso, Analyn, Mao, Xinru, Yang, Nong, Zhang, Yongchang
Publicado 2020

A Bioinspired Soft Robot Combining the Growth Adaptability of Vine Plants with a Coordinated Control System

por Li, Pengchun, Zhang, Yongchang, Zhang, Guangyu, Zhou, Dekai, Li, Longqiu
Publicado 2021

Multi-Risk Assessment of Mine Lithium Battery Fire Based on Quantitative Factor Characterization

por Li, Kuikui, Wang, Yanming, Zhang, Yongchang, Wang, Shasha, Zou, Xiangyu
Publicado 2022

Newly developed anti-angiogenic therapy in non-small cell lung cancer

por Qu, Jingjing, Zhang, Yongchang, Chen, Xue, Yang, Haiyan, Zhou, Chunhua, Yang, Nong
Publicado 2017

Real‐world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non‐driver gene mutation advanced non‐small cell lung cancer

por Wang, Zhongtai, Zhang, Hui, Zhou, Chunhua, Long, Xiaoyan, Guan, Rui, Yang, Nong, Zhang, Yongchang
Publicado 2019

Targeting ALK Rearrangements in NSCLC: Current State of the Art

por Peng, Ling, Zhu, Liping, Sun, Yilan, Stebbing, Justin, Selvaggi, Giovanni, Zhang, Yongchang, Yu, Zhentao
Publicado 2022

Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non–Small Cell Lung Cancer

por Liao, Dehua, Yu, Lun, Shangguan, Dangang, Zhang, Yongchang, Xiao, Bowen, Liu, Ni, Yang, Nong
Publicado 2022

Genomic alterations associated with pseudoprogression and hyperprogressive disease during anti-PD1 treatment for advanced non-small-cell lung cancer

por Zhou, Rui, Tong, Fan, Zhang, Yongchang, Zhang, Ruigang, Bin, Yawen, Zhang, Sheng, Yang, Nong, Dong, Xiaorong
Publicado 2023